0000874015-22-000060.txt : 20220128 0000874015-22-000060.hdr.sgml : 20220128 20220128175851 ACCESSION NUMBER: 0000874015-22-000060 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220126 FILED AS OF DATE: 20220128 DATE AS OF CHANGE: 20220128 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Monia Brett P CENTRAL INDEX KEY: 0001537529 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19125 FILM NUMBER: 22570510 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT STREET 2: C/O ISIS PHARMACEUTICALS, INC. CITY: CARLSBAD STATE: CA ZIP: 92010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330336973 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 FORMER COMPANY: FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2022-01-26 0 0000874015 IONIS PHARMACEUTICALS INC IONS 0001537529 Monia Brett P 2855 GAZELLE COURT CARLSBAD CA 92010 1 1 0 0 Chief Executive Officer Common Stock 2022-01-26 2022-01-26 4 A 0 2194 0.0 A 82424 D Common Stock 2022-01-26 2022-01-26 4 A 0 14004 0.0 A 96428 D Common Stock 2022-01-26 2022-01-26 4 F 0 8032 31.44 D 88396 D Represents shares earned upon the vesting of performance based restricted stock units ("PRSUs") for the second performance period of the grant to the reporting person reported on January 17, 2020. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 58.06% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal. Represents shares earned upon the vesting of performance based restricted stock units ("PRSUs") for the first performance period of the grant to the reporting person reported on January 20, 2021. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 81.37% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal. Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. By: Patrick R. O'Neil, attorney-in-fact For: Brett P. Monia 2022-01-28